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Objective: To evaluate the prevalence and persistence of postoperative glycemic
abnormalities in patients without a history of diabetes, undergoing cardiac surgery (CS).
Methods: Ninety-two patients without diabetes with planned elective CS procedures
at a tertiary institution were evaluated preoperatively and 3months postoperatively for
measures of glucose control including hemoglobin A1c, fasting plasma glucose, 2-h post
oral glucose load, and insulin levels. Data from the hospital course were recorded.
Results: Valid data were available from 61 participants at 3months; 59% had prediabetes
and 10% had diabetes preoperatively by one or more diagnostic criteria and continued
to be dysglycemic at 3months. Preoperative A1C was an independent predictor of
postoperative hyperglycemia (p=0.02). Insulin resistance and BMI rather than glycemic
abnormalities before surgery were associated with a longer duration of the postoperative
insulin infusion (p=0.004, p=0.048).
Conclusion: Seventy percent of CS patients without known diabetes met criteria for
diabetes or prediabetes preoperatively, and these abnormalities persisted after surgery.
Keywords: cardiovascular surgery, hyperglycemia, diabetes mellitus, prediabetes, A1c, insulin resistance
Introduction
The prevalence of diabetesmellitus (DM) and impaired glucose tolerance (IGT) is rising and approx-
imately 79millionUS adults have anundiagnosed glycemic abnormality (1).Dysglycemia is reported
to be an independent risk factor for cardiovascular (CV) events, especially in patients with coronary
artery disease (CAD) and/or undergoing CV procedures (2, 3). These include increased length of
stay, wound infections, mortality, and major cardiac events. The American Diabetes Association
(ADA) now has three criteria to identify dysglycemia, which include a fasting plasma glucose
(FPG), an oral glucose tolerance test (OGTT), and more recently added A1c. The relationship
between pre-surgical glucose abnormalities and postoperative hyperglycemia is currently unclear.
Some studies have shown elevated A1c levels affect postprocedure outcomes in patients with and
without diabetes, especially after cardiac surgery (CS) and post coronary revascularization. Higher
rates of deep sternal wound infections were noted by Alserius in their non-diabetes group if A1c
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was >6% (4). Corpus in his coronary revascularization patients
without diabetes found that an A1C of 6–7% had a significantly
higher rate of major adverse cardiac events (33 vs. 22%, p= 0.04),
target vessel revascularization (31 vs. 19%, p= 0.02), and CV
mortality (4.6 vs. 0.5%, p= 0.03) compared with non-diabetes
patients with hemoglobin A1c levels <6% (5). An abnormal A1c
level may therefore have prognostic significance in prediabetes
patients (5). Unfortunately, some of this data are collected before
A1c cutoffs for diagnosing diabetes were established leading to
an overlap in the diabetes and prediabetes groups by current
criteria. Currently, there are no intervention studies evaluating
postprocedure outcomes after improving glucose control prior
to the procedure, and therefore, algorithms to diagnose glycemic
abnormalities preoperatively, and assess their long-term follow-
up are currently not established.
The objective of this study was to evaluate prevalence of pre-
operative glycemic abnormalities in CS patients without known
diabetes using the threeADAcriteria, determine the course of dys-
glycemia peri- and postoperatively, and evaluate factors associated
with their persistence.
Materials and Methods
Sixty-one patients from the original cohort of 92 consecutive
preoperative patients with no known diabetes, undergoing coro-
nary artery bypass grafting (CABG), valve replacement, thoracic
aortic procedures, or a combined procedure followed up for this
study at a tertiary institution (6). Patients with known diabetes,
organ transplantation, using glucocorticoids, or tube feedings
were excluded. The University of Michigan Institutional Review
Board approved the study, and all participants signed a written
consent.
Demographic data, anthropometric measurements, FPG,
hemoglobin A1c (A1C), 75-g OGTT, and insulin levels were
obtained in all participants at baseline and 3-month postsurgery.
Glucose tolerance classifications recommended by the ADA
were used (7). Normal glucose tolerance was defined as FPG
<100mg/dl and a 2HPG <140mg/dl; impaired fasting glucose
(IFG) was defined as FPG 100–125mg/dl, and diabetes (DM)
as 126mg/dl. 2HPG during a 75 g. OGTT of 140–199mg/dl
was defined as IGT, and 200mg/dl as DM. A1C of 6.5% was
diagnostic of diabetes, 5.7–6.4% as prediabetes. Abnormalities
of one or more of the three criteria FPG, A1C, or OGTT were
considered as dysglycemia. Insulin sensitivity was assessed by
the homeostasis model of assessment-insulin resistance (HOMA-
IR), calculated by fasting Glucose (mg/dl) fasting insulin
(μU/ml)/405.
During the inpatient stay, patients who developed stress
hyperglycemia, defined by either two consecutive point of care
blood glucose (BG) levels 1 h apart >140mg/dl (8) or one BG
>200mg/dl, were started on an institutional insulin infusion pro-
tocol (9). Infusion rates were titrated according to this proto-
col and their duration recorded. Once BG levels reached below
140mg/dl the infusion was weaned and, if there was no sub-
cutaneous insulin requirement, postoperative hyperglycemia was
considered resolved.
The primary outcome of this study was the prevalence of
dysglycemia preoperatively and 3months postoperatively in CS
patients, according to ADA standards (7). Secondary outcomes
were the relationship between preoperative glucose abnormality
and insulin sensitivity with incidence of persistent postoperative
dysglycemia as documented by A1C and OGTT. Finally, the rela-
tionship between preoperative dysglycemia and the duration of
insulin infusion was also evaluated. Length of the insulin infusion
was divided into three categories; <24 h drip duration, 24–48 h
drip duration, and >48 h drip duration.
Assays
Plasma glucose and A1C were measured as described (6). Insulin
was measured by a double-antibody radioimmunoassay using
125I-Human insulin tracer (Linco Research, Inc., St Charles,
MO, USA).
Statistical Analysis
Statistical analysis was performed using PASW18 (IBM, Armonk,
NY, USA). A two sided p-value of <0.05 was considered as
statistically significant. We compared the baseline characteristics,
BG levels, and insulin sensitivity with the use of either T-test or
chi-square test. The concordance between A1Cs, FPGs, and 2-
HRs at admission and at 3months were calculated using weighted
kappa. Preoperative predictors like HbA1c, waist and hip circum-
ference, which were associated with postoperative dysglycemia
were entered into a logistic regression model. Kruskal–Wallis
test was used to determine the relationship between preoperative
dysglycemia and insulin infusion.
Results
From the original cohort of 92 patients, data are reported for
61 participants with valid baseline and follow-up data (Table 1).
Thirty-one participants were excluded due to loss to follow-up,
canceled surgery, withdrawal of consent, death, or lack of com-
plete data. The excluded group had similar baseline characteristics
as those included.
Patients whomet any of the three criteria for prediabetes (59%)
or DM (10%) preoperatively continued to have prediabetes (56%)
or DM (23%) postoperatively. On analyzing each of the diagnostic
criteria separately, 55% of patients with an abnormal A1C stayed
in the prediabetes range and 21% remained in the DM range
postoperatively. About 22% of those with an abnormal 2HPG
remained prediabetic and 44% had DM postoperatively. Similarly,
38% of those with an abnormal FPG remained in the prediabetes
range postoperatively.
The dysglycemic group was older than the group without dys-
glycemia (66 vs. 55 years, p= 0.001). There was no significant
difference between the two groups in regard to other baseline
demographics. A1C, FPG, and 2HPG levels were significantly
higher for those who had dysglycemia by one or more of the
three criteria than those who had no abnormality (Table 2). The
group classified as normal by all three criteria preoperatively had
a significantly lower systolic blood pressure (119 19mm Hg)
compared to the dysglycemic group (133 17mm Hg).
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A1c FPG 2HPG A1c FPG 2HPG
N (%) 18 (30) 31 (51) 26 (43) 12 (20) 12 (20) 39 (64) 19 (31) 17 (28)
Age (years) 5513* 6612* 6511 6710 5813 6213 6410 6714
Male (%) 50 61 69 58 75 59 79 47
BMI (kg/m2) 307.0 296.5 295.8 296.0 328.0 285.9 305.4 287.5
Hip circum (cm) 11319 11219 11116 11314 11023 10317 10318 10515
Waist circum (cm) 10421 10020 10121 10217 10329 9520 9919 9318
Systolic BP (mm Hg) 11920* 13318 13117 12814 12116 12723 13320 12926
Diastolic BP (mm Hg) 7011 7511 7412 7215 6910 7312 7411 7616
FH of diabetes (%) 33 48 54 50 17 49 63 47
Hemoglobin A1C %
(mmol/mol)
5.3 (34)0.3* 6.0 (42)0.3* 5.9 (41)0.5* 5.8 (40)0.6 5.0 (31)0.4* 6.2 (44)0.4* 5.8 (40)0.5 6.0 (42)0.6
FPG (mg/dl) 888* 10218* 10915* 10723* 8911* 9611 1096.5* 1009.7
2HPG (mg/dl) 9124* 11844 12748* 18121* 10621 12861 13862 19736*
Insulin (IU) 2115 2759 3165 5092 2010 2113 248.3 2617
HOMA 4.73.7 8.826 1028 1841 4.52.5 5.03.3 6.62.2 6.34.2
Insulin drip in hours 61 68 54 33 50 62 58 54
*Indicates p-value is significant at 0.05.
TABLE 2 | Differences between patients without any glycemic abnormality and with glycemic abnormality by any one of the three criteria – FPG, 2HPG, or
A1C.
Preoperative Postoperative
Normal Abnormal (all) p-Value Normal Abnormal (all) p-Value
Number of patients 18 40 12 49
HgbA1c % (mmol/mol) 5.3 (34) 5.9 (41) <0.001 5.1 (32) 6.0 (42) <0.001
2HPG (mg/dl) 90.61 122.0 0.001 105.5 128.5 0.03
FPG (mg/dl) 87.55 101.9 <0.001 89.4 97.7 0.02
Insulin 21.37 25.3 0.76 19.8 21.1 0.72
HOMA 4.70 7.9 0.56 4.5 5.2 0.47
TABLE 3 | Preoperative and postoperative incidence of glycemic abnormality by each criteria separately.
By A1c By FPG By 2HPG
N (%) Abnormal (IGT+DM) % N (%) Abnormal (IGT+DM) % N (%) Abnormal (IGT+DM) %
Before surgery 48 51 (48 and 3) 57 42 (39 and 3) 80 20 (15 and 5)
After surgery 37 63 (51 and 12) 69 31 (31 and 0) 73 27 (14 and 13)
IGT, impaired glucose tolerance; DM, diabetes mellitus; 2HPG, 2 h post glucose load; FPG, fasting plasma glucose.
After testing all threeADA criteria,Table 3 shows the postoper-
ative persistence of each glycemic abnormality separately.We then
evaluated the agreement of these tests (κ= 0.39, p< 0.001) and
similarily found 2HPG to have the highest correlation (r= 0.73,
p< 0.001) pre and postoperative. By the described multiple
regression model, only preoperative A1C was an independent
predictor of postoperative dysglycemia (β= 2.2, p= 0.02).
All 61 patients met criteria for initiating an insulin infusion
immediately after surgery. Mean preoperative insulin resistance
and BMI were both higher in the groups that had a longer
duration of insulin infusion (p= 0.004, p= 0.048). There is no
significant association between preoperative A1C, FPG, 2HPG,
and the length of the insulin infusion.
Discussion
In this heterogeneous CS cohort, we found a higher prevalence
of undiagnosed prediabetes by the above three ADA criteria
(59% preoperatively and 57% postoperatively). A study of CABG
patients by McGinn, also found higher rates of prediabetes, (57%
prediabetes and 11% diabetes) (10). McGinn et al. used A1c as
the sole criteria for diagnosing diabetes and as our group has
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previously shown A1C identifies the largest number of patients.
Other studies using FPG and OGTT have identified larger pro-
portions of undiagnosed DM rather than prediabetes (11, 12).
These difference can be explained by our studies use of all three
criteria and the deliberate choice of a heterogeneous CS cohort,
including those undergoing valve, aortic, and CABG operations,
while others have evaluated patients with CAD alone (11, 12). If
CABG patients alone were evaluated in our study, the incidence
of DM would probably have been much higher.
Previous studies have found that FPG and 2HPG were not
equivalent in diagnosing dysglycemia (13, 14) and 2HPG was
a better predictor of CV events and mortality (12). After test-
ing all three ADA diagnostic criteria, we could evaluate the
agreement of these tests and similarly found 2HPG to have the
highest correlation (r= 0.39, p< 0.001) pre and postoperative.
Together these data suggest that although obtaining a 2HPG after
an OGTT is more cumbersome, it may have a predictive utility
exceeding that of FPG or A1C (3, 15). Theoretically, it may be
expected that an operative correction of a cardiac abnormality
should increase physical and exercise capacity and improve or
normalize dysglycemia postoperatively. Unfortunately, the find-
ings reported here did not support this hypothesis, as glycemic
abnormalities persisted in the subjects included in this study,
and were even slightly increased 3months postoperatively. This
postoperative persistence may suggest either a more advanced
impairment of glucose metabolism in this cohort, or a too short
follow-up post surgery that was insufficient to restore normal
glucose tolerance.
Among several baseline characteristics, in multivariable anal-
ysis, preoperative A1C was the only independent predictor of
dysglycemia 3months after surgery. This was similar to the post
myocardial infarction data of Norhammer (12) and also in line
with data reported by Sato et al., who found an association
between A1c and BMI with intraoperative insulin resistance
(16). Similarly, Cammu found that pre-anesthesia BG levels of
>110mg/dl predicted higher intraoperative insulin requirements
(17). However, unlike our study, in Cammu’s study, the diagnosis
of diabetes was made by history only, and as such, patients who
may have had diabetes or prediabetes by other criteria could have
been missed. In addition, several patients without a history of
diabetes underwent an off-pump CABG. Since off-pump patients
are not cooled to any degree and there is no glucose load in the car-
dioplegic solution, insulin requirements would not be comparable
with patients presented in this study (17).
In our cohort, all patients, irrespective of whether they had
DM, prediabetes or normoglycemia by one or more criteria, had
BG excursions above 140mg/dl right after surgery, requiring an
insulin infusion as per our institutional cutoff. The variation in
the frequency of insulin infusions used between studies is prob-
ably due to the different institutional cutoffs to initiate a drip
[cut-off 140mg/dl in our study and 120mg/dl in Ref. (17, 18)].
Several of the CS studies described above evaluate insulin resis-
tance and requirements during surgery. Unfortunately, numer-
ous confounding factors exist at that point including: type of
surgery, hypothermia, cardioplegic solution use, vasopressors,
steroids, type of anesthetics, and other realities. In our experience,
the immediate postoperative duration of the insulin infusion is
the best predictor of recovery from surgical stress and insulin
resistance. We therefore have used the duration of postopera-
tive insulin infusion as a surrogate for recovery and found that,
patients who had longer infusion durations had higher preop-
erative mean BMI, insulin levels, and HOMA-IR, suggestive of
higher insulin resistance. An earlier study has similarly found that
a higher BMI predicted larger perioperative insulin requirement
(17). We found no association between preoperative A1C, FPG,
or 2HPG and the duration of insulin infusion.
Strengths of this study are the combined use of all sensitive
measures for the diagnosis of glucose abnormalities, consistent
with the ADA criteria (7), and obtaining evaluations longitu-
dinally, before and 3months after surgery. To the best of our
knowledge this was not done before, as other studies in various
groups of hospitalized patients have used either a reported his-
tory of diabetes, A1C or FPG levels for the diagnosis of glucose
abnormalities (14, 19). This study also evaluated a truly hetero-
geneous CS population, which includes aortic surgeries, valve
repairs/replacements, and CABG procedures providing a broader
perspective on dysglycemia prevalence and persistence in the CS
population. The main limitations are the small study size and the
short duration of follow-up.We also lost a large number of patients
to follow-up, which could influence interpretation of the results.
Conclusion
Undiagnosed abnormal glycemic states were highly prevalent,
found in 70% of our heterogeneous group of CS patients and
persisted 3months after surgery. Several studies have associated
dysglycemia with poor outcomes (20). This highlights the impor-
tance of dysglycemia screening and post-discharge glucose follow-
up in these patients. Studies of larger size and longer duration are
needed to assess the correlation of this dysglycemia to the future
development of diabetes and its complications.
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